Search Results
Your search for what matches 6165 pages
Showing 4851 - 4900Pig Diagnosed With Lymphoma and Treated at Cornell University Hospital for Animals
Doctors at Cornell University Hospital for Animals in Ithaca, New York, reported what they believe may be the first case of a pig being treated for lymphoma. The animal was described as a 730-pound black-and-white Hampshire pig that was diagnosed with presumptive B-cell lymphoma. The 4-year-old...
Making the Science of Cancer Understandable to a Broad Audience
An educator and scientist for over 30 years, David Sadava, PhD, became interested in the science of cancer while on sabbatical from Claremont Colleges, where he was teaching courses in molecular biology and biotechnology, and went to the City of Hope Medical Center in Duarte, California, to study...
'Alarming Difference' in Survival Outcomes for Young White Men with Melanoma
An “alarming difference” in survival outcomes between young, non-Hispanic white males and females with primary invasive melanoma “highlights the urgent need for both behavioral interventions to promote early detection strategies in young men and further investigation of the biological basis for the ...
Living and Working with Cancer
The most recent figures from the National Cancer Institute put the number of cancer survivors in the United States at nearly 14 million—by 2022, that number is expected to top 18 million. And for the vast majority of those survivors—more than 80%—returning to work after treatment is a top priority...
Western Science Catching Up with Traditional Chinese Medicine
Since the National Institutes of Health Consensus Statement in 1997 concluded that the evidence to date suggests acupuncture is effective in the treatment of chemotherapy-induced nausea and vomiting,1 numerous additional indications for its use in relieving symptoms related to cancer or its...
David Penson, MD, MPH, Receives $2 Million Research Award to Study Prostate Cancer
David Penson, MD, MPH, Professor of Urologic Surgery, Vanderbilt University Medical Center, Nashville, has received a $2 million research award from the Patient-Centered Outcomes Research Institute to study localized prostate cancer. Dr. Penson is also Director of the Vanderbilt Center for Surgical ...
SIDEBAR: Key Issues in Joint Commission Statement by American Psychosocial Oncology Society, Association of Oncology Social Work, and Oncology Nursing Society
It is imperative that [Commission on Cancer]-accredited programs adopt a universal definition of distress. We concur with the National Comprehensive Cancer Network definition of distress as an “unpleasant emotional experience of a psychological (cognitive, behavioral, emotional), social, and/or...
Adolescents, Young Adults with Cancer Often Challenged By Unmet Needs Following Treatment
About 70,000 adolescents and young adults (AYAs) between the ages of 15 and 39 are diagnosed with cancer each year, and in the past 30 years, there has been little or no improvement in survival in this population. In addition to the disease itself, they face many other challenges: reentry into...
Focus on the West Virginia Oncology Society
Now in its fifth year, the West Virginia Oncology Society (WVOS) is already having a major impact on cancer care in the state. In 2010, a joint initiative to develop a statewide cancer clinical trials network was launched by WVOS and the West Virginia University Cancer Center. With funding support...
ASCO's Guideline on Drugs to Lower Breast Cancer Risk
Direct your patients to www.cancer.net/whattoknow so they can learn about ASCO’s recent guideline on drugs to risk of breast cancer for women who have a high risk of developing the disease, including what the recommendations mean for patients and a list of questions to ask the doctor. In addition,...
Conquer Cancer Foundation Grant Recipient 'Pays It Forward' Through Philanthropic Support, Volunteer Service
Dr. Dawn Hershman, Associate Professor of Medicine and Epidemiology at Columbia University Medical Center and leader of the Breast Cancer Program at Herbert Irving Comprehensive Cancer Center, is committed to doing what she can to develop, encourage, and support the next generation of oncology...
A Look Ahead: The Next Decade in Pediatric Oncology
The past 10 years have seen dramatic advances in cancer care, especially in better screening methods and earlier detection, genomic sequencing, and more effective therapies, which have led to increased survival rates in both childhood and adult cancers. According to the National Cancer Institute...
Diane E. Meier, MD: From Early Lessons in Critical Thinking to 'Palliative Care Everywhere'
Although the world is full of suffering, it is full also of the overcoming of it. —Helen Keller, Optimism, 1903 Shortly past 8:00 AM on July 1977, Diane E. Meier, MD, FACP, began the first day of her medical internship. Within minutes she would experience another first: the death of a patient...
FDA Invites Public Input on Menthol in Cigarettes
The U.S. Food and Drug Administration (FDA) has issued an Advance Notice of Proposed Rulemaking (ANPRM) seeking additional information to help the agency make informed decisions about menthol in cigarettes. Despite decades of work to reduce tobacco use in the United States, it continues to be the...
Expert Point of View: Ranjana Advani, MD
At the 2013 ASCO Annual Meeting, Ranjana Advani, MD, the Saul A. Rosenberg, MD, Professor of Lymphoma at Stanford University Medical Center, Palo Alto, California, discussed the promise of the B-cell signaling inhibitors idelalisib and ibrutinib in lymphoma. Biggest Question Given the...
B-cell Receptor Signaling Inhibitors Moving Forward in Lymphoma
Though still in early-phase studies, novel B-cell receptor signaling inhibitors look very promising for the treatment of lymphoma, according to reports from the 2013 ASCO Annual Meeting. Idelalisib in Non-Hodgkin Lymphoma In non-Hodgkin lymphoma (NHL), idelalisib looked impressive as both a single...
Expert Point of View: Jonathan S. Berek, MD
Weekly vs every-3-week therapy is a somewhat controversial area in ovarian cancer, said formal discussant of the MITO-7 trial, Jonathan S. Berek, MD, Director of the Stanford Women’s Cancer Center, Palo Alto, California. “[Japan Clinical Oncology Group (JCOG)]-16 showed a survival advantage for...
Expert Point of View: Judy Garber, MD, MPH
Judy Garber, MD, MPH, Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Center at Dana-Farber Cancer Institute, Boston, was the formal discussant of the GeparSixto paper. The rationale for studying platinum in triple-negative breast cancer is clear: The...
Molecular Tests and Precision Medicine: Not So Fast Now!
The era of the application of genomic, proteomic, and a host of other “omic” analyses to guide decision-making in the therapeutic selection of drugs and biologics is now a key part of cancer care. Medical practice is working to keep up with the scientific advances, evaluate them, and add a variety...
Oncologists Speak Out Against the High Cost of Cancer Drugs
That the United States spends twice as much on health care than other industrialized countries—about $2.8 trillion in 2012—without reaping appreciably better outcomes1 is not news. The topic has been dissected on the front pages of leading newspapers for years and was the subject of the entire...
Maintenance Treatment Delays Progression in Metastatic Colorectal Cancer
For patients with unresectable metastatic colorectal cancer, maintenance treatment with capecitabine (Xeloda) and bevacizumab (Avastin) significantly delayed disease progression and improved overall survival in the phase III CAIRO3 study by the Dutch Colorectal Cancer Group. Miriam Koopman, MD,...
'Best-Ever' Published Prognostic Factor for Early-Stage Type 1 Endometrial Cancer
Immunohistochemical demonstration of the L1 cell adhesion molecule (L1CAM; CD171) “has been shown to be the best-ever published prognostic factor” in Federation Internationale de Gynecologie et d’Obstetrique (FIGO) stage I, type I endometrial cancers “and shows clear superiority over the standardly ...
Role of Erlotinib in EGFR Wild-Type Lung Cancer
I welcomed Matthew Stenger’s Journal Spotlight on the TAILOR trial in the August 15 issue of The ASCO Post (“Docetaxel Superior to Erlotinib in Second-Line Treatment of Advanced Non–Small Cell Lung Cancer With Wild-Type EGFR”). The trial was recently published online in Lancet Oncology,1 and...
Active Surveillance of Very Low-Risk Prostate Cancer Might Not Be Suitable Option for African American Men
African American men with prostate cancer that meets current criteria for very low-risk disease might actually be harboring larger and more aggressive tumors that make active surveillance a less viable option, according to the results of a study published online in the Journal of Clinical Oncology1 ...
I'm Not the Person I Was Before Cancer
I’ve been the caretaker for my husband Will since he suffered three strokes in March 2011, followed by a diagnosis of leukemia a few months later. Now, our roles have reversed, and Will is taking care of me as I go through treatment for stage III follicular non-Hodgkin lymphoma (NHL). It’s been a...
Combining Community Practice and Health Policy Advocacy
Barbara L. McAneny, MD, is a board-certified medical oncologist/hematologist with a robust community practice in Albuquerque, New Mexico. Dr. McAneny, who has held many leadership roles in oncology associations, became a delegate to the American Medical Association (AMA) from ASCO in 2002, was...
ASCO University® Appoints First Editor-in-Chief
ASCO has appointed Daniel G. Haller, MD, as the first Editor-in-Chief of ASCO University®, an eLearning center designed to serve as the educational home for physicians, nurses, advanced practice providers, and patient educators at every stage of their careers. As head of the editorial board, Dr....
What the Latest Breast Cancer News Means for Patients
Direct your patients to www.cancer.net/breastsymposium to read patient-friendly summaries that explain the research highlighted at the 2013 Breast Cancer Symposium and provide a list of questions to ask their doctors and additional resources to learn more. Also, your patients can listen to a...
Ginseng in the Spotlight
I read the study by Barton and colleagues in Journal of the National Cancer Institute with great interest. Ginseng seems potentially to be one treatment for cancer-related fatigue, a poorly understood but debilitating symptom that patients experience during and after treatment.1 I am impressed that ...
ASCO Examines the Future of Cancer Care Over the Next 2 Decades
While the many scientific advances over the past 50 years have led to improved outcomes for millions of patients with cancer—increasing the number of survivors from just 3 million in the 1970s to nearly 14 million today—the next 20 years promise to bring even greater opportunities to improve the...
Dr. Julie Vose Finds the Best of Both Worlds—Patient Care and Cutting-Edge Research—in Academic Medicine
Julie M. Vose, MD, MBA, is the Neumann M. and Mildred E. Harris Professor and Chief of the Division of Hematology/Oncology at the University of Nebraska Medical Center. She grew up in Mitchell, South Dakota, a small town nestled on the banks of the James River. Mitchell is home to the Corn Palace,...
Integrating Genomic Sequencing Into Clinical Care
Although the price of next-generation genomic sequencing is coming way down, making it available to more people interested in determining their risk for disease, figuring out how to interpret the results and applying that information in the routine medical care of individual patients remains a...
Will Funding for Lung Cancer Ever Improve?
Lung cancer is the most common cause of cancer-related death in the world. In the United States alone, an estimated 228,190 new cases of lung cancer and 159,480 deaths from lung cancer will occur in 2013. These are alarming statistics when compared to the next four common causes of cancer-related...
Addressing the Key Clinical Questions in Advanced Melanoma
At the 3rd Annual World Cutaneous Malignancies Congress, in La Jolla, California, Steven J. O’Day, MD, Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute, Los Angeles, addressed what he labeled the “key clinical questions” about...
Tackling Overdiagnosis and Overtreatment, by Words and by Deeds
The complexity of the pathologic condition called cancer,” according to a Viewpoint article in the Journal of the American Medical Association,1 “complicates the goal of early diagnosis.” Failure to recognize that cancers are heterogeneous, and that not all progress to metastases and death, can...
Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries
Reminiscing about his 65 years in medicine, LaSalle Doheny Leffall, Jr, MD, FACS, cites three events in his early childhood that would ultimately lead him to his position today as the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC. First, he was...
The Oncologist as Author: On Guiding Patients Through Cancer
When Tumor Is the Rumor and Cancer Is the Answer is the guidebook to cancer that Kevin P. Ryan, MD, FACP, COL, USAF (ret) wished his patients had during his 30 years of practicing oncology. The book, recently published by AuthorHouse, is an authoritative, inspiring, and even philosophical guide for ...
St. Jude Children's Research Hospital Recognizes Childhood Cancer Awareness Month
Childhood cancer remains the leading cause of death by disease among young Americans. September marks Childhood Cancer Awareness Month, a time to highlight efforts to reduce the disease’s toll on children. At St. Jude, the past year has brought advances in understanding and treating childhood...
Celebrating 2 Decades as a Cancer Survivor
This past June, I celebrated 20 years of being a cancer survivor by throwing myself a party. It was an interesting experience because I learned that many of the 100 guests I invited were also cancer survivors or were family members of cancer survivors, and so we celebrated their lives as well. Our...
The Direction of Immunotherapy Over the Next Decade
The use of immunotherapy to target malignant cells in a variety of cancers—especially the PD-1 inhibitors lambrolizumab and nivolumab in the treatment of metastatic melanoma and the anti–PD-L1 agent MPDL3280A in the treatment of melanoma and lung, kidney, colorectal, and gastric cancers—made...
Communicating the Promise Science Offers to Society
ASCO President Clifford Hudis, MD, FACP, will be serving during a particularly notable year: 2014, the Society’s 50th anniversary. This occasion brings with it much to reflect on, from the advances in the field of oncology to the growth of ASCO’s influence, but Dr. Hudis takes a moment to simply...
Lidia Schapira, MD: Bridging Communication Gaps Between Oncologists and Patients
Communicating the intricacies of oncology care to vulnerable patients with cancer and their caregivers requires a firm grasp of the nuances of language. One of the oncology community’s true champions in the art of breaking down communication barriers is Lidia Schapira, MD, a medical oncologist at...
Couple Pledges $10 Million Gift to MD Anderson’s Head and Neck Cancer Center
The University of Texas MD Anderson Cancer Center in Houston, Texas, recently announced that Charles and Daneen Stiefel, of Raleigh, North Carolina, have pledged $10 million to the Head and Neck Cancer Center at MD Anderson. In honor of their generosity, the institution will name the Charles and...
What Para-Aortic Nodal Involvement Predicts About Survival in PET-CT–Negative Locally Advanced Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy and colleagues evaluated survival outcomes in patients with locally advanced cervical cancer and negative positron-emission tomography/computed tomography (PET-CT) imaging results who underwent...
Undertreatment of Cancer Pain Remains a Persistent Problem in Oncology
Data indicate that for more than 2 decades, cancer pain has been undertreated in the United States. The paradox of this stubborn clinical problem is that oncology has the ability to manage the great majority of cancer pain. To clarify this issue, The ASCO Post recently spoke with nationally...
What Is the Optimal Treatment of Advanced Melanoma?
With exciting targeted and immunotherapeutic agents now part of the arsenal for metastatic melanoma, which drug should move to the head of the line? Mario Sznol, MD, Professor of Medicine at Yale University School of Medicine, New Haven, Connecticut, has been involved in key clinical trials of the...
Three 'Game-Changers' in the Treatment of Melanoma
There have been three “game-changers” in the treatment of melanoma, Mark R. Albertini, MD, Associate Professor of Medicine at the University of Wisconsin in Madison, contended at the Best of ASCO Chicago meeting. The first, he explained, was the recognition of different genetic driver...
SIDEBAR: The Good, the Bad, and the Ugly
Reviewing a study on off-label use of chemotherapy, Monika K. Krzyzanowska, MD, MPH, of Princess Margaret Cancer Centre University of Toronto, reflected on what she called the good, the bad, and the ugly of off-label drug use. “Certainly there are some good aspects about off-label therapy,” she...
A Great Privilege to Die Beneath an Open Sky
It was 1:00 AM, and my beeping pager awakened me. When you’re a surgical oncologist, you know that a page from your chief resident at this hour of the morning usually means someone may need to go to the operating room. And, yes, it was the chief resident about a patient in crisis. Except in this...
Paging Dr. Google: Practicing Oncology in the Era of Social Media and Telemedicine
Over the past few decades, economic and political factors have reshaped oncology, especially in the community setting. To defray risk, we’ve seen a trend toward oncology practices partnering with hospitals or aggregating into larger networks. Moreover, the Internet and the advent of telemedicine...
